DEF: Coya Therapeutics Sets June 25, 2026 Annual Meeting

Sentiment:

Proxy Statement 13 May 2026 8:30 AM

Coya Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors and ratify auditors.

Summary

Coya Therapeutics, Inc. is holding its Annual Meeting of Stockholders on June 25, 2026, virtually via live webcast.
The meeting agenda includes the election of two Class I directors, Wilbur Ross and Dieter Weinand, to serve until the 2029 annual meeting.
Stockholders will also vote to ratify the appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Record Date for determining stockholders entitled to vote is May 1, 2026.
Proxy materials, including the Proxy Statement and the Annual Report for the fiscal year ended December 31, 2025, are available online.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily focused on routine corporate governance matters such as director elections and auditor ratification, with no significant new financial or strategic information.

Positives

The company is holding its annual meeting to ensure corporate governance and provide stockholders with voting opportunities.
The virtual meeting format is intended to increase stockholder participation and reduce costs.
Key leadership positions are being filled with experienced individuals, including the re-election of directors with extensive industry backgrounds.
The company has a clear process for stockholder proposals and nominations for the upcoming annual meeting.

Risks

The staggered three-year terms for directors may delay or prevent a change in management or control of the company.
The company's Certificate of Incorporation and Bylaws allow the Board to change the number of directors and require removal only for cause, potentially limiting stockholder influence on board composition.

Future Outlook

The filing does not contain specific forward-looking financial guidance but focuses on the upcoming annual meeting agenda and corporate governance matters.

Management Comments

The Board believes that the election of Mr. Ross and Mr. Weinand and the appointment of Weaver and Tidwell, L.L.P. as our independent registered public accounting firm for the year ending December 31, 2026 are advisable and in the best interests of the Company and its stockholders.
The virtual format provides the opportunity for participation by a broader group of our stockholders, while reducing costs associated with planning, holding and arranging logistics for in-person meeting proceedings.
We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business.

Industry Context

StockSavvy.ai notes that Coya Therapeutics, Inc. is operating within the biotechnology sector, where annual meetings and director elections are standard procedures for maintaining corporate governance and shareholder engagement. The focus on experienced directors with backgrounds in life sciences and finance is typical for companies in this industry.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director		Wilbur Ross	2026-06-25	Election to serve until the 2029 annual meeting.
Director		Dieter Weinand	2026-06-25	Election to serve until the 2029 annual meeting.
Executive Chairman of the Board	Howard Berman		2026-04-01	Resignation.

Corporate Governance

Change Type	Description	Impact Assessment
Board Structure	The Board of Directors is divided into three classes (Class I, Class II, Class III) with staggered three-year terms.	May delay or prevent a change of management or control.
Director Removal and Vacancies	The authorized number of directors can only be changed by Board resolution. Directors may only be removed for cause. Vacancies are filled by a majority vote of the remaining directors.	Limits stockholder ability to remove directors or fill vacancies outside of Board control.
Audit Committee Charter	The Audit Committee charter outlines responsibilities including auditor selection, financial statement integrity, internal controls, and related party transaction oversight.	Ensures robust financial oversight and compliance.
Compensation Committee Charter	The Compensation Committee charter details responsibilities for executive compensation policies, CEO performance evaluation, and director compensation recommendations.	Governs executive and director compensation practices.
Nominating and Corporate Governance Committee Charter	The Nominating and Corporate Governance Committee charter outlines responsibilities for identifying director nominees, overseeing Board evaluations, and developing corporate governance guidelines.	Manages director nominations and corporate governance standards.
Code of Business Conduct and Ethics	A Code of Business Conduct and Ethics applies to all officers, directors, and employees.	Establishes ethical standards for company conduct.
Anti-Hedging Policy	Prohibits officers, directors, and employees from engaging in certain hedging or monetization transactions involving company securities.	Aims to align insider interests with long-term company performance and prevent speculative trading.

Related Party Transactions

Separation and General Release Agreement with Dr. Howard Berman, including prorated bonus, COBRA premium coverage, and extended stock option vesting and exercise periods following his resignation as Executive Chairman effective April 1, 2026.

Stakeholder Impact

Shareholders: Will vote on director elections and auditor ratification, influencing corporate governance and oversight.
Management and Employees: Subject to the Code of Business Conduct and Ethics and the Anti-Hedging Policy.
Directors: Compensation and election processes are detailed, with specific compensation policies for non-employee directors.

Next Steps

Stockholders to vote on the election of two directors and the ratification of the independent registered public accounting firm at the Annual Meeting on June 25, 2026.
Publication of final voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.
Consideration of stockholder proposals for the 2027 Annual Meeting of Stockholders.

Key Dates

Date	Description
2025-12-31	Fiscal year end for the Annual Report on Form 10-K.
2026-01-01	Start of the fiscal year for which Weaver and Tidwell, L.L.P. are proposed as independent registered public accounting firm.
2026-05-01	Record Date for determining stockholders entitled to vote at the Annual Meeting.
2026-06-13	Approximate date proxy materials are being mailed to stockholders.
2026-06-15	Deadline for requests for paper copies of proxy materials.
2026-06-19	Deadline for beneficial owners to register in advance to attend the Annual Meeting.
2026-06-24	Deadline for proxy cards submitted by mail to be received.
2026-06-25	Date of the Annual Meeting of Stockholders.
2026-06-25	Deadline for proxy votes submitted by telephone or internet.
2027-01-13	Deadline for stockholder proposals to be submitted for inclusion in the 2027 Annual Meeting proxy statement.

Recommendation

hold

This filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic updates, or material non-public information that would warrant a change in investment recommendation. The focus is on corporate governance and director elections.

Keywords

Coya Therapeutics, DEF 14A, Proxy Statement, Annual Meeting, Stockholders Meeting, Director Election, Independent Auditor, Corporate Governance, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.